CD276 and extranodal nasal NK/T cell lymphoma: These novel therapeutic strategies displayed effective targeting and killing ability against NKTCL cells in vitro and in vivo and inhibited the growth of NKTCL tumors in the NSG mouse model, suggesting that B7-H3 is a promising target for NKTCL therapy.